forward. to joining us first and for the I’m you, Jeremy, out and going quarterly recap Officer my the January also and lay the the the progress Executive both on year opportunity thank our past you quarter vision This role call pleased today assuming Thank have and is since on for during webcast. call and first my as company the the Chief to
of well and positions both advancing InspireMD early-stage vascular my drew of part in the changing based have and what companies Cordis share GE large as technologies. XX Much was Healthcare life as experience background, medical many a me device space. would I novel to companies years relevant my a my moment and with take background. on to big the several blue-chip J&J, and including markets first I commercial in leadership like
this in flexibility The postprocedural solution system the events advanced designed stents struts, an I to is advanced the which we traditional and deliver category. caused open-cell stroke. what by from protection protection embolic CGuard most the periprocedural of be would firmly embolic prolapse plaque play platform stent with lead believe CGuard can to to through
major next-generation unique MicroNet superior such has embolization well clinical procedures associated alternative this for stents invasive a as against mitigates and patients or procedure. prolapse shown CGuard’s double technology as outcomes surgical stent types, and layered endarterectomy, as conventional
new with stroke artery of and a has carotid truly care artery for of of disease treatment created protected carotid to management disease prevention. establish and dimension new CGuard the a potential standard
growing stenosis. a The for Bergamo, firsthand the Dr. Micari was by specifically chosen transmission. Dr. and Antonio with of and tight the procedure live case Italy, anatomy In of Leipzig, LINC the the and the brings leading January, audience, in packed was along the interventionalists EPS The from a by together leading I Congress witness was support was conference by observe to in able feedback CGuard tortuous community Hospital cardiologists, EPS International in around enthusiastic, I, Castriota able was at and with surgeons conducted for vascular very extremely interventional from physician Humanitas placement community organizers medical world-renowned CGuard Fausto world. to which the challenging and live
EPS. no or trial practice and associated IRONGUARD complications. disease difficult with of is in patients carotid I to XXX case. enrolled XX-day with X use periprocedural CGuard major their opportunity real-world that had produced EPS of that routine multi-center, CGuard large in multi-specialty artery the suggests analysis clinical CGuard clinical highlighted clinical the of neurological a number outstanding this The which the superiority very also EPS results attend presentations
University benefit. CGuard to Krakow Additionally, and the events sustained EPS showed the safety years, procedural thus five PARADIGM-Extend far, study out long-term longest-running Hospital, trial no device indicating Professor of deducted Musialek related by
for We and broadening treatment. opportunities carotid indications CGuard portfolio continue carotid artery artery to as our disease stroke explore for within of expanding disease EPS well as outside
to LINC well The such at iliac investigator-initiated other demonstrated of research the disease, artery presented peripheral grafts potential studies effectively of other conditions. vein or used be of treatment and subclavian SVGs, disease CGuard treatment as in indications as saphenous as
clinicians We have noted to closely important clinical work have very begun and these who with these results made observations.
continued surgery. portfolio CAD EPS including includes the of Part within of CGuard on strategy use growth to our carotid principles adjunctive the the alternative exploring and procedural to as reverse to a femoral an access. this central adding our a device protection of alternative vascular surgeons vascular focus franchise, flow and of Additionally, is as their our viable to
We leading forward surgeons efforts to working in look pathway. this initiative advancing vascular and our strategic our on with
superior Our the outcomes with of focus, immediate remains awareness however, CGuard being patient creating that EPS. are reported
European market and including our Italy, markets, where We Spain is execution commercial key our growing share continue Germany, Poland, to prioritize rapidly. in
the and part, by CGuard key will COEs. strength our in be or through COE has Europe program The education outreach growing of established European and awareness of large In now parallel in South across Excellence was been physician efforts to extended America. of with and cultivation driven territories India our Centers
available this is a wish COEs. way community. make It driving initiative, long list As Excellence to we key vascular in go and to making program population, utilization, the a possible waiting who of by awareness goal this participate our our result CGuard particularly towards patient surgical to in of will Centers happen broadest a of and our physicians have the
countries distribution Asia other additional product and in America. pursuing contracts with We are Latin Europe, in local distributors and registrations also
reimbursement of we reimbursement effort, in This higher pursue through French in France. an plan exploring with this the alternative of part includes our to partnership a stents conducting application to trial conventional randomized As level a for government. the possibility
EPS artery year. anticipate the world’s the disease Brazil, continue market largest half in regulatory to first the We approval of fifth in CGuard carotid
have potential general, great long-term to in to America, emerge growth. contributors Latin significant and Brazil believe as We our
current Japan these partnerships of and distribution priority as China double more addressable market strategic are Both In for to another both markets China addition, represent and approval Japan EPS gain business. such, we’re our and CGuard the these territories. in than seeking in
strategic completion allow that An an eventual is overriding launch CGuard would the in support the approval IDE to process commercial to EPS us States. a of of objective trial initiate United the
to are Our on are to planned positive agency and ongoing for the a manner FDA discussions This work additional unusual to information. timely is not with the closely accordingly, the according and this to related satisfactorily. process, continuing request the application September, we responding this agency’s in Last line. deliver had progressing time requested
but to into revenue. get wanted comment a the revenue that revenue issued in we fourth will financials with over the pre-announcement our revenue quarter to reported quarter was of about quarter with reported January, XXXX. We fourth fourth $XXX,XXX range begin I in $X,XXX,XXX. representing $X,XXX,XXX XX% total shortly, of Craig $X,XXX,XXX growth of within Consistent the of that
with in QX with year driven XX% period CGuard $XXX,XXX, the Consistent for largely at revenue an in EPS. of full CGuard was increase XXXX, quarters, revenue prior of awareness sterilizer, during grew came And growth of The by growing the demand over since XXXX. to third-party we comparable product to the despite digits. revenue deliver unable the by market majority Notably, growth whom issues portfolio the replaced. for has been our delivered to this quarter CGuard double first being due
but the generated the of All year. artery in date, double-digit endarterectomy. stroke. believe support growth a EPS billion the approximately which record grow $X carotid been remains near-term carotid treatment if on who major CGuard can continues quarters carotid exponentially factors opportunity artery could for are for untreated. estimate are that important million with our currently market disease, all and a carotid we management, XXXX that conventional treated latter opportunity one to can patients CGuard paradigm this there in out has is convert breakthrough, who The data the to showed people be disease an ischemic representing to belief address estimated new based of X.X medical We stents We risk diagnosed
pipeline XXXX our both with We vascular disease, that treat the particular, other strengthened continuing also patents of IP intellectual comment to in the protection but products, globally. has also to the devices fill bolter to but be aneurysms. the in not Most second XXXX issued four brain, of treatment aneurysms it I’d XX portfolio. supporting on ceiling prepared the CGuard, half of issued only Not importantly, only in coverage the MicroNet quite potential covers had products. to a States my abdominal and of aneurysms. conclude remarks in commercial our and our but build like United of includes coverage using to obtained and fruitful property. This aortic issued proved procedures patents aneurysms company
such coronary drug arteries, as as market that as artery contemplated of MicroNet beyond beds superficial vascular other materials, and disease. include to broadened treat been include peripheral peripheral dilution biodegradable devices, carotid artery composed the and to has for coverage various devices artery could materials. scaffolding devices femoral artery including in largest All well Coverage those
continue one to disease. most solutions will non-vascular is elegantly treat of we the and our to protect and to on We what believe intellectual and expand build simple property unique vascular
of commercial Finally, sustained throughout balance and and carefully these our activities operations XXXX, the accountability and expenses intend our cash organization drive and we while resources. will remain undertake results managing to execution on to focused
turn Craig? over the call to Craig review With that, to I’ll the financials.
